CO5200855A1 - Uso de csaids en infecciones por rinovirus - Google Patents

Uso de csaids en infecciones por rinovirus

Info

Publication number
CO5200855A1
CO5200855A1 CO00070099A CO00070099A CO5200855A1 CO 5200855 A1 CO5200855 A1 CO 5200855A1 CO 00070099 A CO00070099 A CO 00070099A CO 00070099 A CO00070099 A CO 00070099A CO 5200855 A1 CO5200855 A1 CO 5200855A1
Authority
CO
Colombia
Prior art keywords
virus
person
cbsp
inhibitor
treatment
Prior art date
Application number
CO00070099A
Other languages
English (en)
Inventor
Susan B Dillon
Griego Sandra D
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of CO5200855A1 publication Critical patent/CO5200855A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un método para tratar el resfriado común o la infección viral respiratoria causada por el rinovirus humano (HRV), otros enterovirus, virus corona, virus gripal, virus paragripal, virus sincitial respiratorio, o adenovirus, en una persona en necesidad del tratamiento, el cual método comprende administrar a dicha persona una cantidad efectiva de un inhibidor de CBSP/p38.1Un método para tratar la neumonía inducida por la gripe en personas en necesidad de dicho tratamiento, el cual método comprende administrar a dicha persona una cantidad efectiva de un inhibidor de CBSP/p38.
CO00070099A 1999-09-17 2000-09-15 Uso de csaids en infecciones por rinovirus CO5200855A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15449499P 1999-09-17 1999-09-17

Publications (1)

Publication Number Publication Date
CO5200855A1 true CO5200855A1 (es) 2002-09-27

Family

ID=22551566

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00070099A CO5200855A1 (es) 1999-09-17 2000-09-15 Uso de csaids en infecciones por rinovirus

Country Status (17)

Country Link
EP (1) EP1223924A4 (es)
JP (1) JP2003516314A (es)
KR (1) KR20020032591A (es)
CN (1) CN1382044A (es)
AR (1) AR025691A1 (es)
AU (1) AU7584500A (es)
BR (1) BR0014041A (es)
CA (1) CA2385722A1 (es)
CO (1) CO5200855A1 (es)
CZ (1) CZ2002939A3 (es)
HU (1) HUP0204333A3 (es)
IL (1) IL148329A0 (es)
NO (1) NO20021301L (es)
PL (1) PL363116A1 (es)
TR (1) TR200200673T2 (es)
WO (1) WO2001019322A2 (es)
ZA (1) ZA200202060B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
EP1337255A4 (en) * 2000-10-19 2006-01-25 Smithkline Beecham Corp USE OF P38 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY COUGH
JP4524072B2 (ja) 2000-10-23 2010-08-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規化合物
ATE385777T1 (de) * 2002-03-20 2008-03-15 Elan Pharma Int Ltd Nanopartikelzusammensetzungen von mitogen- aktivierten protein (map) kinase inhibitoren
RU2004132847A (ru) * 2002-04-05 2006-08-20 Берингер Ингельхайм Фарма Гмбх Унд Ко.Кг (De) Способ лечения гиперсекреции слизи
WO2004004725A2 (en) * 2002-07-09 2004-01-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
JP4593953B2 (ja) * 2004-03-30 2010-12-08 杏林製薬株式会社 ライノウイルス感染症の予防薬
WO2006017505A2 (en) * 2004-08-04 2006-02-16 Schering Corporation Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases
AR053346A1 (es) 2005-03-25 2007-05-02 Glaxo Group Ltd Compuesto derivado de 8h -pirido (2,3-d) pirimidin -7 ona 2,4,8- trisustituida composicion farmaceutica y uso para preparar una composicion para tratamiento y profilxis de una enfermedad mediada por la quinasa csbp/ rk/p38
CN101977625A (zh) * 2008-03-20 2011-02-16 克里斯特·坦诺 物质在制备治疗感冒药物中的应用
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
US20110229437A1 (en) * 2009-09-17 2011-09-22 Mutual Pharmaceutical Company, Inc. Method of Treating Asthma with Antiviral Agents
GB201010196D0 (en) * 2010-06-17 2010-07-21 Respivert Ltd Methods
GB201010193D0 (en) 2010-06-17 2010-07-21 Respivert Ltd Medicinal use
US11389663B2 (en) 2011-04-01 2022-07-19 Bioregentech, Inc. Laser assisted wound healing protocol and system
US11730760B2 (en) 2011-04-01 2023-08-22 The Bioregentech Institute, Inc. Laser assisted wound healing protocol and system
GB201611712D0 (en) 2016-07-02 2016-08-17 Hvivo Services Ltd Methods and compounds for the treatment or prevention of severe or persistent influenza
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071144A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. USE OF P38 INHIBITORS TO REDUCE DUX4 EXPRESSION
GB201721793D0 (en) * 2017-12-22 2018-02-07 Hvivo Services Ltd Methods and compunds for the treatment or prevention of hypercytokinemia and severe influenza
WO2021216754A1 (en) * 2020-04-21 2021-10-28 Spring Discovery, Inc. Use of p38 mapk inhibitors for prevention and treatment of aging and aging-related disorders and for boosting an immune system

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3927216A (en) * 1971-06-01 1975-12-16 Icn Pharmaceuticals 1,2,4-Triazol E-3-carboxamides for inhibiting virus infections
US3984396A (en) * 1971-06-01 1976-10-05 Icn Pharmaceuticals, Inc. 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
US5656644A (en) * 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
US5658903A (en) * 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
AP9700912A0 (en) * 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
EP1140083A4 (en) * 1999-01-08 2004-01-02 Smithkline Beecham Corp NEW CONNECTIONS

Also Published As

Publication number Publication date
HUP0204333A2 (en) 2003-05-28
BR0014041A (pt) 2003-07-15
WO2001019322A3 (en) 2001-10-04
EP1223924A2 (en) 2002-07-24
PL363116A1 (en) 2004-11-15
JP2003516314A (ja) 2003-05-13
WO2001019322A2 (en) 2001-03-22
CA2385722A1 (en) 2001-03-22
NO20021301D0 (no) 2002-03-15
TR200200673T2 (tr) 2002-12-23
ZA200202060B (en) 2003-05-28
HUP0204333A3 (en) 2004-07-28
NO20021301L (no) 2002-05-16
KR20020032591A (ko) 2002-05-03
AU7584500A (en) 2001-04-17
AR025691A1 (es) 2002-12-11
CZ2002939A3 (cs) 2002-11-13
IL148329A0 (en) 2002-09-12
CN1382044A (zh) 2002-11-27
EP1223924A4 (en) 2004-07-14

Similar Documents

Publication Publication Date Title
CO5200855A1 (es) Uso de csaids en infecciones por rinovirus
ES2603086T3 (es) Uso de la daptomicina
ES2163504T3 (es) Formas de dosificacion de liberacion controlada de azitromicina.
ATE475423T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen
BRPI0509140A (pt) processos para o tratamento de infecção por hiv
DK1411932T3 (da) Kombinationsterapi med substituerede oxazolidinoner
AR045870A1 (es) Terapia de combinacion para la infeccion de virus de hepatitis c
UY27875A1 (es) Prodrogas 2 ' y 3 ' de nucleósidos modificados para tratar flaviviridae
ECSP045069A (es) Uso de flibanserina en el tratamiento de trastornos sexuales
FR2759581B1 (fr) Dispositif de traitement, notamment par moxa, de type acupressure
ES2137981T3 (es) Tratamiento combinado por agentes antimediaticos y antiviricos de resfriados comunes.
PA8502901A1 (es) Tratamiento de combinacion con il-1ra y compuestos que inhiben el procesamiento y la liberacion de il-1
EE200200107A (et) Kiire algtoimega selektiivse serotoniini tagasihaaramise inhibiitori kasutamine ravimi valmistamiseks, mis on ette nähtud seksuaalse funktsioonihäireravimiseks
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
AR021155A1 (es) Tratamiento de desordenes neuroticos
BR9811473A (pt) Infecção por rinovìrus inibida por óxido nìtrico
MX2008002456A (es) Uso de ambroxol para el tratamiento de infecciones por rinovirus.
ATE451934T1 (de) Pharmazeutische zusammensetzung zur behandlung von rhinitiden
DE602005016552D1 (de) Parapocken-viren in kombination mit anderen antiviralen mitteln zur behandlung von hiv/aids
BR0317539A (pt) Métodos e composições para o tratamento de infecções por vìrus da herpes usando inibidores seletivos da ou ciclooxigenase-2 ou inibidores da ciclooxigenase-2 em combinação com agentes antivirais
BR0107960A (pt) Tratamento de condições alérgicas e inflamatórias
HUP0302233A2 (hu) Virális betegségek kezelésére IL-18-cal és IL-18 kombinációkkal
BR0206775A (pt) Uso de um medicamento para tratar um indivìduo infectado com hiv, por combinação de imunização com interrupção estruturada do tratamento anti-retrovirótico
DK1670489T3 (da) Brug af xenon med hypotermi til behandling af neonatal asfyksi
ATE545423T1 (de) Mittel zur behandlung von lungenkrebs

Legal Events

Date Code Title Description
FC Application refused